Jornal de Ensaios Clínicos
Acesso livre

Abstrato

Que fatores levam a tempos prolongados de revisão regulamentar para novos medicamentos no Japão?

Shigetomo Yoneda, Ryuta Asada, Shinobu Shimizu, Shunsuke Ono e Takuhiro Yamaguchi

Objective: Among all the new drugs approved in Japan, the regulatory review time for some greatly exceeds the median each year. However, to our knowledge, no reports have detailed why the review times were prolonged in these instances. In this study, we examined new applications (NDAs) whose review times were more than twice as long as the median each year in order to pinpoint the cause of delayed approval.
Methods: We analyzed 564 NDAs that were approved in Japan between 2005 and 2011.
Results: Thirty-eight NDAs were found to have prolonged review times. Of the 38 NDAs, the most popular therapeutic categories were oncology drugs and vaccines, and 28 of the drugs had already been approved in foreign countries when approval was granted in Japan, some with lag times of more than 36 months. This observation suggests that prolonged regulatory review time further worsens lags in drug approval. “Problem related to clinical data” was cited as the most common reason for prolonged review time. For most of the NDAs categorized into this group, additional clinical trials were conducted during the same review time without NDA withdrawal because the clinical study design was inappropriate, a deficiency in the evidence of a dosage regimen was observed, or efficacy was not confirmed in a confirmatory study trial.
Conclusion: Our analyses of these trial details indicate the importance of determining the optimal dosage regimen carefully and utilizing objective endpoints in clinical trials.